David Borges Sells 10,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 10,000 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the chief accounting officer owned 5,906 shares in the company, valued at $111,918.70. This trade represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Performance

NASDAQ:OMER traded down $0.04 during mid-day trading on Tuesday, reaching $19.28. The stock had a trading volume of 1,314,611 shares, compared to its average volume of 1,716,966. The firm has a 50 day moving average price of $11.93 and a two-hundred day moving average price of $11.81. The stock has a market capitalization of $1.40 billion, a P/E ratio of 15.06 and a beta of 2.54. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. Research analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.

Institutional Trading of Omeros

Several large investors have recently modified their holdings of OMER. International Assets Investment Management LLC raised its position in Omeros by 16.0% during the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 800 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares during the period. State of Wyoming purchased a new position in shares of Omeros during the fourth quarter valued at approximately $25,000. AQR Capital Management LLC raised its holdings in shares of Omeros by 7.2% during the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 1,532 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in Omeros by 12.1% in the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 1,637 shares during the period. 48.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright restated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Omeros currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.